To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Bob Duggan, chairman and co-CEO of Summit Therapeutics Inc. SMMT, is capitalizing on a remarkable 689% stock surge to ...

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical ...

The 11,000-square-foot condo, located on the top two floors of the 57-story tower, offers views of the water and the Miami ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On Monday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $20.5 which represents a decrease of $-0.71 or -3.35% from the prior close of $21.21. The stock opened at $21.16 and ...

Bob Duggan is cashing in on a 689% rally in his Summit Therapeutics Inc. to buy one of the most expensive condos ever sold in Miami’s Brickell neighborhood.Duggan is buying a $33 million two-story ...

Oncotelic's Cautionary Note on Forward-Looking Statements ...

Citi analyst Yigal Nochomovitz has reiterated their bullish stance on RCUS stock, giving a Buy rating on October 21. Yigal Nochomovitz’s ...

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.